Combined effect of cisplatin and lymphokine-activated killer cells on A549 cells of non-small cell lung cancer

We studied the ability of lymphokine-activated killer cells to lyse A549 human non-small cell lung cancer cells after preincubation with cisplatin. Lymphokine-activated killer cells obtained after incubation of human blood lymphocytes with interleukin-2 were characterized by high expression of natural killer cell antigens and activation molecules. Lymphokine-activated killer cells produced potent cytotoxic effect on intact A549 cells and lysed tumor cells survived after treatment with cisplatin in concentrations of IC₅₀ and IC₃₀. Cisplatin in noncytotoxic concentrations did not increase lytic activity of lymphokine-activated killer cells. __________ Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 144, No. 8, pp. 198–201, August, 2007